CN104487450A - 多肽序列设计及其在多肽介导的siRNA传递中的应用 - Google Patents
多肽序列设计及其在多肽介导的siRNA传递中的应用 Download PDFInfo
- Publication number
- CN104487450A CN104487450A CN201280057898.5A CN201280057898A CN104487450A CN 104487450 A CN104487450 A CN 104487450A CN 201280057898 A CN201280057898 A CN 201280057898A CN 104487450 A CN104487450 A CN 104487450A
- Authority
- CN
- China
- Prior art keywords
- sirna
- polypeptide
- cell
- mixture
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 140
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 76
- 230000001404 mediated effect Effects 0.000 title abstract description 5
- 238000012772 sequence design Methods 0.000 title description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 102
- 229920001184 polypeptide Polymers 0.000 claims description 99
- 239000000203 mixture Substances 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000006907 apoptotic process Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 230000030279 gene silencing Effects 0.000 abstract description 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 description 26
- 238000001890 transfection Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 18
- 210000001163 endosome Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 238000013461 design Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
- 108010005636 polypeptide C Proteins 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000004475 Arginine Substances 0.000 description 7
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 7
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 235000017103 tryptophane Nutrition 0.000 description 7
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 6
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- 241000699802 Cricetulus griseus Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000009881 electrostatic interaction Effects 0.000 description 5
- 238000002189 fluorescence spectrum Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 102000029797 Prion Human genes 0.000 description 4
- 108091000054 Prion Proteins 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 239000006035 Tryptophane Substances 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 125000001165 hydrophobic group Chemical group 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001338 self-assembly Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000009871 tenuigenin Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000001493 Cyclophilins Human genes 0.000 description 2
- 108010068682 Cyclophilins Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000000799 fusogenic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 108010043655 penetratin Proteins 0.000 description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 1
- 108010003545 C1 peptide Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100013786 Mus musculus Gapdh gene Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
名称 | 序列 | 序列代号 |
C1M | FQFNFQFNGGGPKKKRKV | (SEQ.ID.NO 1) |
C1M1 | FQFNFQFNGGGPKPKRKV | (SEQ.ID.NO 2) |
C1M2 | FQFNFQFNFQFNGGGPKKKRKV | (SEQ.ID.NO 3) |
C1M3 | FQFNFQFNFQFNWSQPKPKRKV | (SEQ.ID.NO 4) |
C1M4 | FQFNFQFNFQFNGGGPKPKRKV | (SEQ.ID.NO 5) |
C1M5 | FQFNFQFNFQFNGGGCHHRRRRRRHC | (SEQ.ID.NO 6) |
C1M6 | FQFNFQFNFQFNGGGCPKPKRKVC | (SEQ.ID.NO 7) |
名称 | 序列 | 序列代号 |
E3M | RLTLHLRLELTLHLE | (SEQ.ID.NO 8) |
E3M1 | RWTWHWRWEWTWHWE | (SEQ.ID.NO 9) |
A7M | RHALAHLLHKLKHLLHALAHR | (SEQ.ID.NO 10) |
A7M1 | RHALAHLLHRLRHLLHALAHR | (SEQ.ID.NO 11) |
名称 | 序列 | 序列代号 |
C6M | RLWRLWLRLWRRLWRLLR | (SEQ.ID.NO 12) |
C6M1 | RLWRLLWRLWRRLWRLLR | (SEQ.ID.NO 13) |
C6M2 | RLWRLLWHLWRHLWRLLR | (SEQ.ID.NO 14) |
C6M3 | RLWHLLWRLWRRLHRLLR | (SEQ.ID.NO 15) |
C6M4 | HLLRLLLRLWHRLWRLLR | (SEQ.ID.NO 16) |
C6M5 | HLWHLLLRLWRRLLRLLR | (SEQ.ID.NO 17) |
C6M6 | GLWHLLLHLWRRLLRLLR | (SEQ.ID.NO 18) |
C6M7 | GLWHLLLHLWRRHHRHHR | (SEQ.ID.NO 19) |
C6M8 | GLWHLHLHLWRRHHRLLR | (SEQ.ID.NO 20) |
C6M9 | GLWHLLLHLWHRLLRHHR | (SEQ.ID.NO 21) |
名称 | 序列 | 序列代号 |
MW1 | MWKSKIGSWILVRWAMWSKKRPKP | (SEQ.ID.NO 22) |
MW2 | MWKSHIGSWILVRWAMWSHKRPKP | (SEQ.ID.NO 23) |
MW3 | MWKSKISWILVSKPGLCKKRPKP | (SEQ.ID.NO 24) |
MW4 | MHKSKISWHLVSKPGLCHKRPKP | (SEQ.ID.NO 25) |
名称 | 序列 | 序列代号 |
C6-Dr | rLLrLLLrLWrrLLrLLr | (SEQ.ID.NO 26) |
C6-D | rllrlllrlwrrllrllr | (SEQ.ID.NO 27) |
C6M1-Dr | rLWrLLWrLWrrLWrLLr | (SEQ.ID.NO 28) |
C6M1-D | rlwrllwrlwrrlwrllr | (SEQ.ID.NO 29) |
C6M3-Dr | rLWHLLWrLWrrLHrLLr | (SEQ.ID.NO 30) |
C6M3-D | rlwhllwrlwrrlhrllr | (SEQ.ID.NO 31) |
C6M6-Dr | GLWHLLLHLWrrLLrLLr | (SEQ.ID.NO 32) |
C6M6-D | glwhlllhlwrrllrllr | (SEQ.ID.NO 33) |
名称 | 序列 | 序列代号 |
STR-C1 | CH3(CH2)16-GGGPKPKRKV | (SEQ.ID.NO 40) |
STR-HK | CH3(CH2)16-HHHPKPKRKV | (SEQ.ID.NO 41) |
STR-HKC | CH3(CH2)16-HHHCPKKKRKVC | (SEQ.ID.NO 42) |
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211606804.7A CN116549655A (zh) | 2011-11-24 | 2012-11-23 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
CN201811108533.6A CN110251682B (zh) | 2011-11-24 | 2012-11-23 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161563591P | 2011-11-24 | 2011-11-24 | |
US61/563,591 | 2011-11-24 | ||
PCT/CA2012/050843 WO2013075244A1 (en) | 2011-11-24 | 2012-11-23 | Peptide sequence design and use thereof for peptide-mediated sirna delivery |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811108533.6A Division CN110251682B (zh) | 2011-11-24 | 2012-11-23 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
CN202211606804.7A Division CN116549655A (zh) | 2011-11-24 | 2012-11-23 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104487450A true CN104487450A (zh) | 2015-04-01 |
CN104487450B CN104487450B (zh) | 2018-09-21 |
Family
ID=48468958
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280057898.5A Active CN104487450B (zh) | 2011-11-24 | 2012-11-23 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
CN202211606804.7A Pending CN116549655A (zh) | 2011-11-24 | 2012-11-23 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
CN201811108533.6A Active CN110251682B (zh) | 2011-11-24 | 2012-11-23 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211606804.7A Pending CN116549655A (zh) | 2011-11-24 | 2012-11-23 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
CN201811108533.6A Active CN110251682B (zh) | 2011-11-24 | 2012-11-23 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
Country Status (4)
Country | Link |
---|---|
US (3) | US9259483B2 (zh) |
EP (3) | EP3375457B1 (zh) |
CN (3) | CN104487450B (zh) |
WO (1) | WO2013075244A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112979758A (zh) * | 2021-03-05 | 2021-06-18 | 扬州博科文化发展有限公司 | 一类多肽及其制备多肽花青素复合物的方法与应用 |
CN114007654A (zh) * | 2019-04-17 | 2022-02-01 | 阿迪根有限公司 | 用于分子的细胞内递送的肽和纳米颗粒 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103694317A (zh) * | 2013-12-12 | 2014-04-02 | 南京工业大学 | 一种阳离子型聚肽,以及基于所述聚肽的siRNA基因转染试剂及其制备方法 |
CN104725478B (zh) | 2013-12-18 | 2018-12-25 | 纳肽得有限公司 | 多肽化合物、多肽化合物与siRNA的组装体及其应用 |
WO2018085460A2 (en) * | 2016-11-02 | 2018-05-11 | Flagship Pioneering, Inc. | Compositions and methods for cell delivery |
WO2019226940A1 (en) * | 2018-05-24 | 2019-11-28 | Sirnaomics, Inc. | Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics |
EP3597223A1 (en) * | 2018-07-17 | 2020-01-22 | Centre National De La Recherche Scientifique | Peptides for use as cell-penetrating peptides |
CN117700490B (zh) * | 2022-12-30 | 2024-06-11 | 云南沃森生物技术股份有限公司 | 一种四支链多肽及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101041079A (zh) * | 1999-12-30 | 2007-09-26 | 诺瓦提斯公司 | 用于基因治疗的新的胶体合成载体 |
CN101939329A (zh) * | 2007-08-30 | 2011-01-05 | 滑铁卢大学 | 以氨基酸配对为基础的自组装肽和方法 |
WO2011020188A1 (en) * | 2009-08-21 | 2011-02-24 | University Of Waterloo | Peptide sequences and peptide-mediated sirna delivery |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955343A (en) | 1992-12-28 | 1999-09-21 | Massachusetts Institute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
US5614503A (en) | 1993-11-12 | 1997-03-25 | Aronex Pharmaceuticals, Inc. | Amphipathic nucleic acid transporter |
US6040295A (en) | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
GB9504761D0 (en) | 1995-03-09 | 1995-04-26 | Unilever Plc | Amphiphilic peptide and analogs thereof |
AU1799097A (en) * | 1995-12-21 | 1997-07-17 | University Court Of The University Of Dundee, The | Presentation of antigen, introduced into the cells by stimulation of macropinocytosis |
US6387700B1 (en) | 1996-11-04 | 2002-05-14 | The Reagents Of The University Of Michigan | Cationic peptides, Cys-Trp-(LYS)n, for gene delivery |
CA2291074C (en) | 1997-05-21 | 2008-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
US7306784B2 (en) | 1998-06-20 | 2007-12-11 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
EP1242052A4 (en) | 1999-12-29 | 2003-07-02 | A James Mixson | HISTIDIN COPOLYMER AND METHODS OF USE THEREOF |
SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
US20040147027A1 (en) | 2003-01-28 | 2004-07-29 | Troy Carol M. | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
US20080299104A1 (en) * | 2004-07-01 | 2008-12-04 | California Institute Of Technology | Methods for detecting agents involved in neuronal apoptosis and compositions thereof |
US7084248B2 (en) | 2004-07-14 | 2006-08-01 | Gene Tools, Llc | Peptide composition and method for delivering substances into the cytosol of cells |
US7579318B2 (en) | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
WO2007069090A2 (en) | 2005-12-06 | 2007-06-21 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
AU2006325030B2 (en) | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
BRPI0620806B8 (pt) | 2005-12-30 | 2022-07-05 | Evonik Roehm Gmbh | complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição |
US7521232B2 (en) * | 2006-05-31 | 2009-04-21 | Icx Nomadics, Inc. | Emissive species for clinical imaging |
WO2008033285A2 (en) | 2006-09-15 | 2008-03-20 | The Trustees Of Culumbia University In The City Of New York | Delivery of double-stranded rna into the central nervous system |
WO2008063113A1 (en) | 2006-11-20 | 2008-05-29 | Cepep Iii Ab | Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf |
JP5635512B2 (ja) | 2008-09-16 | 2014-12-03 | カリエム・アーメド | 遺伝子調節化合物の改良された送達のための化学的に修飾された細胞透過性ペプチド |
WO2011087804A2 (en) * | 2009-12-21 | 2011-07-21 | Medtronic, Inc. | Peptide-polynucleotide compositions, and methods for transfecting a cell with dna and treatment of neurodegenerative disease |
WO2011127210A1 (en) * | 2010-04-06 | 2011-10-13 | Massachusetts Institute Of Technology | Targeted delivery of nucleic acids |
-
2012
- 2012-11-23 EP EP18170087.3A patent/EP3375457B1/en active Active
- 2012-11-23 US US14/359,873 patent/US9259483B2/en active Active
- 2012-11-23 CN CN201280057898.5A patent/CN104487450B/zh active Active
- 2012-11-23 EP EP20174827.4A patent/EP3725333B1/en active Active
- 2012-11-23 WO PCT/CA2012/050843 patent/WO2013075244A1/en active Application Filing
- 2012-11-23 EP EP12852395.8A patent/EP2782926B1/en active Active
- 2012-11-23 CN CN202211606804.7A patent/CN116549655A/zh active Pending
- 2012-11-23 CN CN201811108533.6A patent/CN110251682B/zh active Active
-
2015
- 2015-12-29 US US14/983,194 patent/US9603946B2/en active Active
-
2017
- 2017-01-17 US US15/407,802 patent/US9950073B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101041079A (zh) * | 1999-12-30 | 2007-09-26 | 诺瓦提斯公司 | 用于基因治疗的新的胶体合成载体 |
CN101939329A (zh) * | 2007-08-30 | 2011-01-05 | 滑铁卢大学 | 以氨基酸配对为基础的自组装肽和方法 |
WO2011020188A1 (en) * | 2009-08-21 | 2011-02-24 | University Of Waterloo | Peptide sequences and peptide-mediated sirna delivery |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114007654A (zh) * | 2019-04-17 | 2022-02-01 | 阿迪根有限公司 | 用于分子的细胞内递送的肽和纳米颗粒 |
CN112979758A (zh) * | 2021-03-05 | 2021-06-18 | 扬州博科文化发展有限公司 | 一类多肽及其制备多肽花青素复合物的方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104487450B (zh) | 2018-09-21 |
EP3725333A1 (en) | 2020-10-21 |
US20160175456A1 (en) | 2016-06-23 |
EP2782926B1 (en) | 2018-07-04 |
US20140350082A1 (en) | 2014-11-27 |
US9603946B2 (en) | 2017-03-28 |
EP3375457A1 (en) | 2018-09-19 |
CN110251682B (zh) | 2022-12-06 |
US9259483B2 (en) | 2016-02-16 |
EP3725333B1 (en) | 2023-08-23 |
WO2013075244A1 (en) | 2013-05-30 |
US20170128582A1 (en) | 2017-05-11 |
CN116549655A (zh) | 2023-08-08 |
EP3375457B1 (en) | 2020-06-24 |
EP2782926A1 (en) | 2014-10-01 |
US9950073B2 (en) | 2018-04-24 |
EP2782926A4 (en) | 2015-11-04 |
CN110251682A (zh) | 2019-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104487450B (zh) | 多肽序列设计及其在多肽介导的siRNA传递中的应用 | |
Huang et al. | Delivery of nucleic acids and nanomaterials by cell‐penetrating peptides: Opportunities and challenges | |
ES2694726T3 (es) | Conjugados peptídicos específicos de tejido y métodos | |
Gooding et al. | siRNA delivery: from lipids to cell‐penetrating peptides and their mimics | |
Kim et al. | RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system | |
US20140051646A1 (en) | Cell penetrating peptides | |
Baoum et al. | Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing | |
JP2007145761A (ja) | 細胞膜透過性ペプチド修飾多糖−コレステロールまたは多糖−脂質非ウイルス性ベクターおよびその製造方法 | |
WO2012113846A1 (en) | A system for cargo delivery into the cells | |
Soudah et al. | AntimiR-155 cyclic peptide–PNA conjugate: synthesis, cellular uptake, and biological activity | |
CA3101446A1 (en) | Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics | |
Soudah et al. | CLIP6-PNA-peptide conjugates: non-endosomal delivery of splice switching oligonucleotides | |
WO2015090212A1 (zh) | 多肽及其作为递送载体的用途 | |
US20140179765A1 (en) | Phase changing formulations of nucleic acid payloads | |
Haque et al. | Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide | |
US9970002B2 (en) | Compositions and methods for functional nucleic acid delivery | |
Grijalvo et al. | Synthesis and in vitro inhibition properties of oligonucleotide conjugates carrying amphipathic proline-rich peptide derivatives of the sweet arrow peptide (SAP) | |
Hamilton et al. | Non-viral siRNA delivery vectors: dendritic molecular transporter and molecular transporter nanovectors for target gene silencing | |
Kim et al. | Dimeric human β-defensin 3 as a universal platform for intracellular delivery of nucleic acid cargos | |
Langel | Methods for CPP Functionalization with Oligonucleotides | |
Gamboa | Characterization and Evaluation Of Hybrid Collagen/Cell Penetrating Peptides for Sirna Delivery | |
CN104356199A (zh) | 一种硬脂酰修饰的多肽类可降解基因载体及其制备方法与应用 | |
Zhang et al. | Self-Assembly of Peptide–Lipid Nanoparticles for the Efficient Delivery of Nucleic Acids | |
Lundin | Delivery of gene-regulating agents: Internalization mechanisms and novel vectors | |
Mo | Cell penetrating peptide-based polyplexes for siRNA delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181127 Address after: N2T1W9, Crescent 93, Waterloo Valley Ridge, Ontario, Canada Patentee after: Naptide Co., Ltd. Address before: 215123 No. 18 Dongwang Road, Suzhou Industrial Park, Jiangsu Province Co-patentee before: Chen Pu Patentee before: Baoshide Electric Tools Co., Ltd., Suzhou |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190828 Address after: 21 Building, Academician Port, 171 Jinshui Road, Licang District, Qingdao City, Shandong Province Patentee after: Naptide (Qingdao) Biomedical Co., Ltd. Address before: N2T1W9, Waterloo Ridge Crescent 93, Ontario Patentee before: Naptide Co., Ltd. |
|
TR01 | Transfer of patent right |